Cargando…
Efficacy of a two-dose hepatitis B vaccination with a novel immunostimulatory sequence adjuvant (Heplisav-B) on patients with chronic liver disease: a retrospective study
BACKGROUND: Patients with chronic liver disease (CLD) are more likely to have severe morbidity and mortality due to superimposed acute or chronic hepatitis B virus (HBV) infection and should receive routine vaccination against the virus. Heplisav-B is a two-dose, inactivated, yeast-derived vaccine t...
Autores principales: | Kwon, Joshua Y., Daoud, Nader, Ghoz, Hassan, Yataco, Maria L., Farraye, Francis A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813651/ https://www.ncbi.nlm.nih.gov/pubmed/36704654 http://dx.doi.org/10.21037/tgh-22-12 |
Ejemplares similares
-
Cost-Effectiveness of an Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) in Patients With Inflammatory Bowel Disease
por: Corral, Juan E, et al.
Publicado: (2020) -
Transient Hepatitis B Surface Antigenemia Following Immunization with Heplisav-B
por: Corsini Campioli, Cristina, et al.
Publicado: (2021) -
21. Current and Nadir CD4+ Counts Are Associated with Heplisav-B Seroprotection Rates in People with HIV
por: Schnittman, Samuel, et al.
Publicado: (2020) -
2287. Recently Approved HEPLISAV-B(R) [Hepatitis B Vaccine (Recombinant), Adjuvanted] Shows a Higher Proportion of Subjects Achieving Seroprotection With a More Consistent Immune Response Compared With Engerix-B(R) [Hepatitis B Vaccine (Recombinant)] in Three Comparative Trials
por: Hyer, Randall N, et al.
Publicado: (2018) -
Oral Contraceptive Pills Are an Effective Method of Preventing Pregnancy in Women With Crohn’s Disease
por: Daoud, Nader D, et al.
Publicado: (2021)